Procedural Pharmaceutical Lessons From Early Adopters

Experienced glaucoma surgeons share practical pearls on integrating sustained drug delivery into practice.

By: Christine Funke, MD, J. Morgan Micheletti, MD, FACS, Jason Bacharach, MD, Shivani S. Kamat, MD, Arkadiy Yadgarov, MD, Steven R. Sarkisian, Jr., MD, Robert F. Melendez, MD, MBA, Syril K. Dorairaj, MD, and, Pranav Vasu, MPH, Savak “Sev” Teymoorian, MD, MBA, Reza Alizadeh, MD, Lorraine M. Provencher, MD, Jai G. Parekh, MD, MBA, FAAO, Manjool Shah, MD, Inder Paul Singh, MD, Huda Sheheitli, MD, Reena A. Garg, MD, Zarmeena Vendal, MD

Glaucoma Physician September 1, 2026 Page(s): 16-20

Objective:

To share insights from experienced glaucoma surgeons on integrating sustained drug delivery into glaucoma management.

Approach:

Patient Selection and Counseling: Surgeons discuss the importance of individualized treatment plans and effective communication with patients regarding sustained drug delivery options.

Key Findings:

Sustained-release pharmaceuticals like Durysta and iDose TR provide alternatives to daily topical therapy.
Patient education and counseling are essential for the acceptance of procedural pharmaceuticals.
Surgeons highlight the importance of individualized treatment options over traditional drop therapy.

Interpretation:

The integration of sustained drug delivery into glaucoma treatment requires a shift in approach among surgeons and patients.

Limitations:

The article does not provide quantitative data on the effectiveness of sustained drug delivery compared to traditional therapies.
Insights are based on individual experiences and may not be applicable to all practices.

Conclusion:

Surgeons are adapting their approaches to include sustained drug delivery as a potential option in glaucoma management.